NCT06626893 (AL-TOMICA) is a NA clinical trial of Functional tests in Myeloid Leukemia, Acute, sponsored by Azienda Ospedaliero-Universitaria di Parma.

Who is sponsoring NCT06626893?

NCT06626893 is sponsored by Azienda Ospedaliero-Universitaria di Parma.

What drugs are being tested in NCT06626893?

Interventions in NCT06626893: Functional tests, Next Generation Sequencing analysis, Microvesicles analysis.

What condition does NCT06626893 study?

NCT06626893 studies Myeloid Leukemia, Acute, Leukemia, Acute Lymphoblastic.

Is NCT06626893 still recruiting?

NCT06626893 is currently recruiting now. Last updated 4 October 2024.

Last reviewed 2024-10-04 · How we verify

NCT06626893: AL-TOMICA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Integrative "Omics" Approaches for Leukemia Target Identification and Matched Therapeutic Intervention

Recruiting now NA Last updated 4 October 2024

What this trial tests

NA trial testing Functional tests in Myeloid Leukemia, Acute in 100 participants. Currently enrolling.

Timeline

1 March 2022

Primary endpoint
1 March 2025

1 March 2025

Quick facts

Lead sponsor	Azienda Ospedaliero-Universitaria di Parma
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	100
Start date	1 March 2022
Primary completion	1 March 2025
Estimated completion	1 March 2025
Sites	8 locations across Italy

Drugs / interventions tested

Functional tests — full drug profile →
Next Generation Sequencing analysis
Microvesicles analysis — full drug profile →

Conditions studied

Myeloid Leukemia, Acute — all drugs for Myeloid Leukemia, Acute →
Leukemia, Acute Lymphoblastic — all drugs for Leukemia, Acute Lymphoblastic →

Sponsor

Azienda Ospedaliero-Universitaria di Parma — full company profile →

Who can join

18 and older, any sex, with Myeloid Leukemia, Acute or Leukemia, Acute Lymphoblastic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to use multiple "omics" sciences to more thoroughly investigate Acute Recurrent/Refractory Leukemias (LA R/R) after conventional therapy in order to identify new targets and/or therapeutic approaches, in patients with a diagnosis of Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma B(ALL-B), Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma T (ALL-T), Acute Biphenotypic Leukemia/II as defined by WHO( World Health Organization) 2016, relapsed or refractory after at least one line of therapy. The main question that the trial aims to answer is: "Can molecules with known biological activity be active and represent possible new therapeutic strategies in relapsed/refractory Acute Leukemias on the basis of response profiles identified through the integration of next-generation chemogenomic and functional analyses? " It is expected that a minimum of 100 patients, male and female, aged 18 years and older, will be included. To participate in the study, the patient must consent to the performance on biological specimen (peripheral blood and bone marrow) of genetic/molecular and/or "omics" investigations performed with modern sequencing techniques, such as Next Generation Sequencing, Single Cell RNA Seq (scRNAseq), RT-qPCR(Quantitative reverse transcription polymerase chain reaction). These investigations will aim to improve the understanding of the genetic and molecular alterations of her disease. In addition, your cells will be used in the laboratory to perform in vitro sensitivity studies (drug response profiling - DRP) that aim to simultaneously test a set of hundreds of drugs to assess sensitivity or resistance profiles of your disease cells with the aim of identifying specific new therapies that target specific cellular mechanisms. In addition, part of the biological sample will be used for investigations of the bone marrow microenvironment and the "secretome", i.e., cell signaling molecules and methods. In order to accomplish this study, samples from peripheral or bone marrow blood taken during routine investigations performed during follow-up and re-evaluation visits for the patient's disease as per normal clinical practice will be used. Among the investigations that will be performed on the blood sample will be the genetic/molecular and/or omics and preclinical investigations described above.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Acute Myeloid Leukemia in Older Patients: From New Biological Insights to Targeted Therapies.
Niscola P, Gianfelici V, Catalano G, Giovannini M, et al · · 2024 · cited 10× · PMID 39590121 · DOI 10.3390/curroncol31110490
Single-cell RNA sequencing: enhancing the predictive accuracy of tumor immunotherapy efficacy.
Zhou W, Huang Z, Wu Z, Tang M, et al · · 2025 · cited 3× · PMID 40857744 · DOI 10.1042/ebc20253017

Verify or expand the search:

Other trials of Functional tests

Trials testing the same drug.

NCT05137483 — Cognitive Impairment and Upper Extremity Performance in COPD · unknown
NCT05084703 — Reproducibility of Functional Shoulder Tests for the Return to Sport of Patients Operated on Previous Shoulder Instabili · NA · unknown
NCT03162081 — Medication Misuse and Dependence Among Elderly · active not recruiting

Other recruiting trials for Myeloid Leukemia, Acute

Currently open trials in the same condition.

NCT06904066 — Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients W · Phase 1 · recruiting
NCT06697600 — A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers · NA · recruiting
NCT06764459 — Molecular Characterization of Patients With Acute Myeloid Leukemia and the Impact of Clonal Evolution in the Response to · recruiting
NCT04678401 — IS-free Treg HaploHCT · Phase 1 · recruiting

Other Azienda Ospedaliero-Universitaria di Parma trials

Trials by the same sponsor.

NCT07360366 — Interprofessional Collaboration in the Cardiac Intensive Care Unit (CICU): An Action-Research Training Project · NA · not yet recruiting
NCT06888167 — Food (Poly)Phenol Metabotypes and Beta-cell Mass and Function. · NA · recruiting
NCT06876818 — Predictive Cardio-Metabolic Trascrictomics Trajectories In The Barilla Offspring Follow-Up Study · active not recruiting
NCT07419178 — A New Diagnostic Algorithm to Non-invasively Track Fibrotic Changes in Myeloproliferative Neoplasms Based on C-C Chemoki · NA · recruiting
NCT05936944 — Role of Natural Light in the Prevention of Delirium After Cardiac Surgery: a Prospective Observational Study With Histor · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06626893 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Azienda Ospedaliero-Universitaria di Parma
Last refreshed: 4 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06626893.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing